Strides Pharma Science Future Growth
Future criteria checks 3/6
Strides Pharma Science is forecast to grow earnings and revenue by 112.8% and 10% per annum respectively. EPS is expected to grow by 113.2% per annum. Return on equity is forecast to be 14.5% in 3 years.
Key information
112.8%
Earnings growth rate
113.2%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 10.0% |
| Future return on equity | 14.5% |
| Analyst coverage | Low |
| Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11
Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?
Dec 28Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 10Could The Strides Pharma Science Limited (NSE:STAR) Ownership Structure Tell Us Something Useful?
Nov 25Insider Buying: The Strides Pharma Science Limited (NSE:STAR) Non-Executive Director Just Bought 52% More Shares
Aug 17What You Can Learn From Strides Pharma Science Limited's (NSE:STAR) P/E
Aug 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2026 | 49,619 | 4,070 | 9,000 | N/A | 4 |
| 3/31/2025 | 45,135 | 2,921 | 7,262 | N/A | 4 |
| 3/31/2024 | 41,139 | -413 | 5,503 | N/A | 3 |
| 12/31/2023 | 39,535 | -1,525 | N/A | N/A | N/A |
| 9/30/2023 | 37,806 | -2,280 | 3,043 | 3,903 | N/A |
| 6/30/2023 | 36,783 | -924 | N/A | N/A | N/A |
| 3/31/2023 | 36,884 | -2,212 | -505 | 444 | N/A |
| 12/31/2022 | 35,680 | -1,824 | N/A | N/A | N/A |
| 9/30/2022 | 34,976 | -2,241 | -2,101 | -1,144 | N/A |
| 6/30/2022 | 33,220 | -3,909 | N/A | N/A | N/A |
| 3/31/2022 | 30,703 | -4,602 | -4,012 | -2,578 | N/A |
| 12/31/2021 | 31,127 | -4,425 | N/A | N/A | N/A |
| 9/30/2021 | 31,504 | -2,830 | -1,188 | 1,572 | N/A |
| 6/30/2021 | 32,224 | -543 | N/A | N/A | N/A |
| 3/31/2021 | 33,159 | 2,545 | 1,840 | 4,814 | N/A |
| 12/31/2020 | 30,260 | 28 | N/A | N/A | N/A |
| 9/30/2020 | 29,264 | 589 | 970 | 2,699 | N/A |
| 6/30/2020 | 28,480 | 1,266 | N/A | N/A | N/A |
| 3/31/2020 | 27,520 | 492 | 548 | 2,048 | N/A |
| 12/31/2019 | 35,828 | 2,859 | N/A | N/A | N/A |
| 9/30/2019 | 34,203 | 2,169 | -1,519 | 1,896 | N/A |
| 6/30/2019 | 32,248 | 745 | N/A | N/A | N/A |
| 3/31/2019 | 21,784 | 840 | -2,690 | 601 | N/A |
| 12/31/2018 | 28,547 | -93 | N/A | N/A | N/A |
| 9/30/2018 | 28,090 | 139 | N/A | N/A | N/A |
| 6/30/2018 | 28,451 | 415 | N/A | N/A | N/A |
| 3/31/2018 | 28,451 | 544 | -2,156 | 1,871 | N/A |
| 12/31/2017 | 35,810 | 1,050 | N/A | N/A | N/A |
| 9/30/2017 | 36,593 | 1,124 | N/A | N/A | N/A |
| 6/30/2017 | 35,357 | 1,712 | N/A | N/A | N/A |
| 3/31/2017 | 27,554 | 2,335 | N/A | 2,881 | N/A |
| 12/31/2016 | 37,237 | 2,840 | N/A | N/A | N/A |
| 9/30/2016 | 36,573 | 2,410 | N/A | N/A | N/A |
| 6/30/2016 | 34,189 | 2,168 | N/A | N/A | N/A |
| 3/31/2016 | 28,622 | 1,317 | N/A | 732 | N/A |
| 12/31/2015 | 24,901 | 1,152 | N/A | N/A | N/A |
| 9/30/2015 | 12,962 | 860 | N/A | N/A | N/A |
| 6/30/2015 | 12,105 | 244 | N/A | N/A | N/A |
| 3/31/2015 | 11,958 | 16 | N/A | 834 | N/A |
| 3/31/2014 | 10,728 | -1,867 | N/A | -2,173 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STAR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).
Earnings vs Market: STAR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: STAR is expected to become profitable in the next 3 years.
Revenue vs Market: STAR's revenue (10% per year) is forecast to grow slower than the Indian market (10.2% per year).
High Growth Revenue: STAR's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STAR's Return on Equity is forecast to be low in 3 years time (14.5%).